HSD3B1 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant HSD3B1.
|Application ||WB, IHC|
|Calculated MW||42252 Da|
|Other Names||3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type I, 3-beta-HSD I, Trophoblast antigen FDO161G, 3-beta-hydroxy-Delta(5)-steroid dehydrogenase, 3-beta-hydroxy-5-ene steroid dehydrogenase, Progesterone reductase, Steroid Delta-isomerase, Delta-5-3-ketosteroid isomerase, HSD3B1, 3BH, HSDB3A|
|Target/Specificity||HSD3B1 (AAH31999.1, 1 a.a. ~ 373 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||HSD3B1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1.Gestational Trophoblastic Tumors and Related Tumor-Like Lesions.Shih IM, Mazur MT, Kurman RJ.Blaustein's Pathology of the Female Genital Tract 2011, 1075-1135, DOI: 10.1007/978 -1-4419-0489-8_202.Advances in the diagnosis of gestational trophoblastic tumors and tumor-like lesions.Mao TL, Shih IM.Expert Opin. Med. Diagn. (2009) 3(4):371-3803.Chorangiocarcinoma: A Case Report and Review of the Literature.Ariel I, Boldes R, Weintraub A, Reinus C, Beller U, Arbel R.Int J Gynecol Pathol. 2009 May;28(3):267-71.4.HSD3B1 as a novel trophoblast-associated marker that assists in the differential diagnosis of trophoblastic tumors and tumorlike lesions.Mao TL, Kurman RJ, Jeng YM, Huang W, Shih IM.Am J Surg Pathol. 2008 Feb;32(2):236-42.5.Trophogram, an immunohistochemistry-based algorithmic approach, in the differential diagnosis of trophoblastic tumors and tumorlike lesions.Shih IeM.Ann Diagn Pathol. 2007 Jun;11(3):228-34.
If you have any additional inquiries please email technical services at email@example.com.